French pharma major Sanofi (Euronext: SAN) has signed a 250 million euro ($273 million) research collaboration and licence option agreement in metabolic disease with Exscientia, a UK company involved in artificial intelligence (AI)-driven drug discovery.
Exscientia will apply its unique platform to identify and validate combinations of drug targets that could work synergistically and be amenable to its bispecific-small-molecule design strategy.
"Sanofi has put together an excellent experimental backbone for this collaboration and we look forward to delivering high-value projects for the company"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze